MCID: BRS049
MIFTS: 51

Breast Carcinoma in Situ malady

Genetic diseases, Cancer diseases, Rare diseases categories

Summaries for Breast Carcinoma in Situ

About this section
Sources:
34MalaCards
See all sources

Fully expand this MalaCard

Download this MalaCard
MalaCards: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast cancer and ductal carcinoma in situ. An important gene associated with Breast Carcinoma in Situ is VEGFC (vascular endothelial growth factor C), and among its related pathways are Fanconi anemia pathway and Homologous Recombination Repair. The compounds topotecan and crcs have been mentioned in the context of this disorder. Affiliated tissues include breast and testes, and related mouse phenotypes are no phenotypic analysis and limbs/digits/tail.

Aliases & Classifications for Breast Carcinoma in Situ

About this section
Sources:
9Disease Ontology, 41NCIt, 59SNOMED-CT, 63UMLS, 28ICD9CM, 26ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Genetic diseases, Cancer diseases, Rare diseases


Aliases & Descriptions:

breast carcinoma in situ 9
non-infiltrating carcinoma of breast 9
carcinoma in situ of breast 9


External Ids:

Disease Ontology9 DOID:8791
NCIt41 C3641
ICD9CM28 233.0
ICD1026 D05

Related Diseases for Breast Carcinoma in Situ

About this section
Sources:
18GeneCards, 19GeneDecks
See all sources

Diseases in the Breast Cancer family:

Inflammatory Breast Carcinoma Breast Benign Neoplasm
breast carcinoma in situ Familial Breast Cancer
Chek2-Related Susceptibility to Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Breast Cancer, Type 3
Breast Cancer, Early-Onset

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 83)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer30.7BRCA1, BRCA2
2ductal carcinoma in situ30.6CDH1, ERBB2, BRCA1, TP53, BRCA2
3ovarian cancer29.9VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2
4poland syndrome10.2
5female breast carcinoma10.2
6hypoxia10.2
7breast-ovarian cancer, familial, 210.1BRCA2
8chordoma10.1KRT19
9nodular goiter10.1KRT19, VEGFC
10follicular thyroid carcinoma10.1VEGFC, KRT19
11papillary thyroid carcinoma10.1MET, VEGFC
12brca1 and brca2 hereditary breast and ovarian cancer10.1BRCA2, BRCA1
13cystadenoma10.1VEGFC, BRCA1
14fallopian tube cancer10.1BRCA1, BRCA2
15peritoneal carcinoma10.1BRCA1, BRCA2
16bilateral breast cancer10.1BRCA1, BRCA2
17lynch syndrome10.0BRCA2, BRCA1
18familial colorectal cancer10.0BRCA2, BRCA1
19tongue cancer10.0CDH1, VEGFC
20dysgerminoma10.0BRCA2, BRCA1
21microinvasive gastric cancer10.0VEGFC, CDH1
22cowden disease10.0BRCA1, BRCA2
23gynecomastia10.0BRCA1, BRCA2
24intraocular melanoma10.0MET, VEGFC
25laryngeal benign neoplasm10.0TP53, VEGFC
26bloom syndrome10.0BRCA1, BRCA2
27tongue squamous cell carcinoma10.0KRT19, CDH1
28neuroendocrine carcinoma10.0KRT19, CDH1
29nasopharynx carcinoma10.0TP53, CDH1
30aplastic anemia10.0BRCA2, BRCA1
31biliary tract neoplasm10.0ERBB2, MET
32renal clear cell carcinoma10.0CDH1, MET
33lung benign neoplasm10.0TP53, MET, KRT19
34breast fibroadenoma10.0ERBB2, VEGFC
35cervical cancer10.0VEGFC, TP53, KRT19
36synovial sarcoma10.0KRT19, MET, CDH1
37follicular adenoma10.0CDH1, KRT19, MET
38malignant mesothelioma10.0CDH1, MET
39fanconi's anemia10.0BRCA1, BRCA2
40malignant mixed mullerian tumor10.0ERBB2, TP53
41esophageal cancer10.0VEGFC, TP53
42li-fraumeni syndrome10.0BRCA1, BRCA2, TP53
43bladder transitional cell carcinoma10.0TP53, VEGFC, CDH1
44xeroderma pigmentosum10.0TP53, BRCA1
45benign mesothelioma10.0MET, KRT19
46ataxia telangiectasia10.0BRCA1, BRCA2, TP53
47thyroid cancer, anaplastic10.0CDH1, MET, TP53
48sarcoma10.0MET, BRCA2, TP53
49tubular adenocarcinoma10.0ERBB2, CDH1
50thyroid cancer10.0TP53, VEGFC, KRT19, MET

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Symptoms for Breast Carcinoma in Situ

About this section

Drugs & Therapeutics for Breast Carcinoma in Situ

About this section
Sources:
6CenterWatch, 43NIH Clinical Center, 7ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Breast Carcinoma in Situ

Drug clinical trials:

Search ClinicalTrials for Breast Carcinoma in Situ

Search NIH Clinical Center for Breast Carcinoma in Situ

Search CenterWatch for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

About this section

Anatomical Context for Breast Carcinoma in Situ

About this section
Sources:
34MalaCards
See all sources

MalaCards organs/tissues related to Breast Carcinoma in Situ:

34
Breast, Testes

Animal Models for Breast Carcinoma in Situ or affiliated genes

About this section
Sources:
38MGI
See all sources

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

38 (show all 19)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.4CDH1, KRT19, MET, TP53
2MP:00053718.4TP53, BRCA2, BRCA1, MET, ERBB2
3MP:00053888.3TP53, BRCA1, MET, ERBB2
4MP:00053868.2ERBB2, MET, BRCA1, BRCA2, TP53
5MP:00053908.1TP53, BRCA2, BRCA1, ERBB2, KRT19
6MP:00036317.7TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
7MP:00053817.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
8MP:00053807.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
9MP:00028737.5TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
10MP:00053857.5VEGFC, TP53, BRCA1, MET, ERBB2, KRT19
11MP:00053787.3TP53, BRCA2, BRCA1, MET, ERBB2, KRT19
12MP:00053877.3VEGFC, SDC1, TP53, BRCA2, BRCA1, MET
13MP:00107717.0SDC1, TP53, BRCA2, BRCA1, ERBB2, KRT19
14MP:00053897.0SDC1, TP53, BRCA2, BRCA1, ERBB2, KRT19
15MP:00053766.8VEGFC, SDC1, TP53, BRCA2, BRCA1, MET
16MP:00020066.7CDH1, SDC1, TP53, BRCA2, BRCA1, MET
17MP:00053796.7SDC1, TP53, BRCA2, BRCA1, MET, ERBB2
18MP:00053846.7SDC1, TP53, BRCA2, BRCA1, MET, ERBB2
19MP:00107686.4VEGFC, SDC1, TP53, BRCA2, BRCA1, MET

Publications for Breast Carcinoma in Situ

About this section
Sources:
53PubMed
See all sources

Articles related to Breast Carcinoma in Situ:

(show all 40)
idTitleAuthorsYear
1
Mondor's disease in a patient previously treated for breast carcinoma in situ: a case report. (22595929)
2012
2
Differences in breast carcinoma in situ between menopausal and premenopausal women. (21617240)
2011
3
Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. (21149333)
2010
4
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. (20565829)
2010
5
Might the widespread use of statin drugs explain the increase in prevalence of breast carcinoma in situ? (19896281)
2010
6
Prevalence of breast carcinoma in situ in the United States. (19706857)
2009
7
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. (18665169)
2008
8
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). (18317962)
2008
9
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. (17244359)
2007
10
Cigarette smoking and risk of breast carcinoma in situ. (17700252)
2007
11
Oral contraceptive use and risk of breast carcinoma in situ. (18006914)
2007
12
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. (17063272)
2007
13
Quality of life for women diagnosed with breast carcinoma in situ. (17050872)
2006
14
Molecular classification of breast carcinoma in situ. (17375183)
2006
15
Oral contraceptive use and risk of breast carcinoma in situ (United States). (17006721)
2006
16
Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. (15540225)
2005
17
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. (15841074)
2005
18
Impact of reproductive factors and lactation on breast carcinoma in situ risk. (15054874)
2004
19
Proliferative lesions of the breast: carcinoma in situ. (15022899)
2003
20
The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. (14659121)
2003
21
Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. (12611452)
2003
22
Oral contraceptives and the risk of ductal breast carcinoma in situ. (14572155)
2003
23
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. (12670886)
2003
24
Lifetime recreational exercise activity and risk of breast carcinoma in situ. (14601085)
2003
25
DNA content and cell number determination in microdissected samples of breast carcinoma in situ. (12118344)
2002
26
Breast carcinoma in situ: risk factors and screening patterns. (11734598)
2001
27
p53 mutations and expression in breast carcinoma in situ. (10623666)
2000
28
Breast carcinoma in situ in a male. Report of a case diagnosed by nipple discharge cytology. (9622698)
1998
29
Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. (9071907)
1997
30
Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. (8692711)
1996
31
Biological heterogeneity of breast carcinoma in situ. (8651598)
1996
32
Male breast carcinoma in situ. Report of a case diagnosed by nipple discharge cytology alone. (7654052)
1995
33
Breast carcinoma in situ. (20169700)
1992
34
Breast carcinoma-in-situ: an emerging problem in Singapore. (1329232)
1992
35
Receptors for estrogen and progesterone in breast carcinoma in situ. (1295456)
1992
36
Ten-year follow-up of breast carcinoma in situ in Connecticut. (1365682)
1992
37
Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. (1677296)
1991
38
Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up. (1657650)
1991
39
Breast carcinoma in situ. (2535929)
1989
40
Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. (2990246)
1985

Variations for Breast Carcinoma in Situ

About this section

Expression for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
2BioGPS, 16Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
51PathCards, 31KEGG, 56Reactome, 39NCBI BioSystems Database, 61Thomson Reuters, 54QIAGEN, 5Cell Signaling Technology, 62Tocris Bioscience, 55R&D Systems, 58SinoBiological, 13EMD Millipore
See all sources

Pathways related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 54)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.7BRCA1, BRCA2
2
Show member pathways
9.7BRCA2, BRCA1
39.7CDH1, MET
49.7CDH1, MET
59.7CDH1, MET
69.4BRCA1, TP53
79.4BRCA1, TP53
89.4BRCA1, TP53
99.4BRCA1, TP53
109.4TP53, BRCA1
119.4TP53, BRCA1
12
Show member pathways
ATM Signaling Pathway39
9.4TP53, BRCA1
139.4TP53, CDH1
14
Show member pathways
9.4CDH1, MET, VEGFC
159.3KRT19, TP53
169.3MET, SDC1
179.3VEGFC, MET, ERBB2
189.2CDH1, SDC1
199.2MET, ERBB2, CDH1
209.2MET, ERBB2, CDH1
21
Show member pathways
9.2MET, ERBB2, CDH1
22
Show member pathways
9.1TP53, BRCA2, BRCA1
239.1TP53, BRCA2, BRCA1
24
Show member pathways
9.1TP53, BRCA2, BRCA1
25
Show member pathways
9.1TP53, BRCA2, BRCA1
26
Show member pathways
9.1CDH1, MET, TP53
27
Show member pathways
9.0ERBB2, MET, TP53
289.0ERBB2, MET, TP53
29
Show member pathways
9.0TP53, BRCA2, ERBB2
308.9CDH1, ERBB2, TP53
31
Show member pathways
Signal transduction PTEN pathway61
8.9TP53, ERBB2, CDH1
32
Show member pathways
8.8CDH1, ERBB2, MET, VEGFC
33
Show member pathways
8.8VEGFC, MET, ERBB2, CDH1
348.8MET, BRCA1, TP53, VEGFC
358.7VEGFC, TP53, BRCA1, CDH1
36
Show member pathways
8.7ERBB2, MET, TP53, VEGFC
37
Show member pathways
8.7VEGFC, TP53, MET, ERBB2
38
Show member pathways
8.7VEGFC, TP53, MET, ERBB2
398.6CDH1, BRCA1, BRCA2, TP53
408.6TP53, BRCA1, MET, ERBB2
41
Show member pathways
Wnt Signaling Pathway NetPath39
8.6CDH1, TP53, SDC1
428.5ERBB2, BRCA1, BRCA2, TP53
43
Show member pathways
Integrin-mediated cell adhesion39
Focal Adhesion39
8.5VEGFC, SDC1, MET, ERBB2
448.2ERBB2, MET, TP53, SDC1
45
Show member pathways
Development EGFR signaling via PIP361
Development PDGF signaling via MAPK cascades61
Apoptosis and survival Anti apoptotic action of membrane bound ESR161
Signaling of Hepatocyte Growth Factor Receptor39
Development EGFR signaling via small GTPases61
Development Neurotrophin family signaling61
Apoptosis and survival NGF signaling pathway61
Apoptosis and survival Role of CDK5 in neuronal death and survival61
8.2SDC1, TP53, MET, ERBB2
46
Show member pathways
7.9VEGFC, TP53, BRCA2, BRCA1, MET, ERBB2
477.8VEGFC, TP53, BRCA2, MET, ERBB2, CDH1
48
Show member pathways
7.8VEGFC, TP53, BRCA1, MET, ERBB2, CDH1
49
Show member pathways
7.8VEGFC, TP53, BRCA1, MET, ERBB2, CDH1
50
Show member pathways
Signaling Pathways in Glioblastoma39
7.7CDH1, ERBB2, MET, BRCA1, BRCA2, TP53

Compounds for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
46Novoseek, 12DrugBank, 25HMDB, 62Tocris Bioscience, 52PharmGKB, 30IUPHAR, 3BitterDB
See all sources

Compounds related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 108)
idCompoundScoreTop Affiliating Genes
1topotecan46 1211.4BRCA1
2crcs469.4MET, TP53, CDH1
3o6-methylguanine469.4BRCA2, TP53, CDH1
4methylmethanesulfonate469.4BRCA2, TP53, BRCA1
55-methylcytosine46 2510.3CDH1, BRCA1, TP53
64-hydroxytamoxifen469.3BRCA1, ERBB2, BRCA2
7leptomycin b46 6210.2CDH1, BRCA1, TP53
8gefitinib46 52 1211.2CDH1, ERBB2, MET
9suberoylanilide hydroxamic acid469.1ERBB2, CDH1, TP53
10oxaliplatin46 52 1211.1TP53, BRCA1, ERBB2
11p003469.1CDH1, BRCA2, KRT19, BRCA1
12folate469.1ERBB2, CDH1, BRCA2, BRCA1
13agar469.1BRCA1, CDH1, ERBB2, MET
14methotrexate52 46 1211.0BRCA2, ERBB2, BRCA1, CDH1
15indole-3-carbinol469.0CDH1, BRCA1, BRCA2, TP53
16bortezomib46 52 1211.0TP53, ERBB2, BRCA1
17phosphotyrosine469.0BRCA1, CDH1, ERBB2, MET
18geldanamycin46 52 62 1211.9MET, TP53, CDH1, ERBB2
19resveratrol46 62 25 1211.9BRCA1, BRCA2, ERBB2, TP53
20irinotecan46 52 1210.9CDH1, TP53, ERBB2
21matrigel468.9CDH1, VEGFC, BRCA2, KRT19, MET
22thymidylate468.8TP53, BRCA1, CDH1, ERBB2
235fluorouracil468.8CDH1, ERBB2, TP53, BRCA1
24heparin46 30 25 1211.8VEGFC, CDH1, ERBB2, BRCA1, MET
25bleomycin46 129.8TP53, BRCA1, BRCA2
26estradiol46 25 1210.7BRCA2, KRT19, VEGFC, BRCA1
27genistein46 30 62 3 25 1213.7BRCA2, CDH1, BRCA1, ERBB2, MET
28oligonucleotide468.7BRCA1, TP53, BRCA2, MET, VEGFC
29proline468.6CDH1, BRCA1, TP53, BRCA2, MET
30ly294002468.6VEGFC, TP53, ERBB2, MET, CDH1
31steroid468.6KRT19, ERBB2, BRCA2, BRCA1, MET
32docetaxel46 52 62 1211.5CDH1, BRCA1, ERBB2, TP53, BRCA2
33doxorubicin46 52 1210.5TP53, MET, CDH1, ERBB2, BRCA1
34etoposide46 52 62 1211.5ERBB2, TP53, CDH1, BRCA1, BRCA2
35tamoxifen46 52 30 1211.5BRCA1, CDH1, BRCA2, TP53, ERBB2
36phosphatidylinositol468.5VEGFC, BRCA2, BRCA1, MET, ERBB2, CDH1
37thymidine46 259.3KRT19, MET, BRCA1, TP53, VEGFC, BRCA2
38p002468.3BRCA2, BRCA1, MET, CDH1, KRT19, ERBB2
39cycloheximide468.1BRCA1, TP53, BRCA2, MET, ERBB2, KRT19
40tyrosine468.0CDH1, VEGFC, BRCA1, MET, KRT19, ERBB2
41paclitaxel46 52 1210.0TP53, BRCA1, ERBB2, CDH1, KRT19, BRCA2
42testosterone46 62 25 1211.0BRCA1, VEGFC, MET, ERBB2, KRT19, CDH1
43retinoic acid46 258.9BRCA2, CDH1, KRT19, MET, BRCA1, TP53
44serine467.8TP53, MET, CDH1, ERBB2, KRT19, BRCA1
45vegf467.7TP53, VEGFC, KRT19, BRCA1, MET, ERBB2
46adriamycin467.7CDH1, KRT19, ERBB2, MET, BRCA1, BRCA2
47cisplatin46 52 62 1210.7ERBB2, MET, BRCA2, TP53, CDH1, KRT19
48paraffin467.4ERBB2, KRT19, MET, BRCA1, CDH1, BRCA2
49progesterone46 30 62 25 1211.4TP53, VEGFC, MET, ERBB2, CDH1, KRT19
50estrogen467.3VEGFC, CDH1, BRCA2, BRCA1, MET, ERBB2

GO Terms for genes affiliated with Breast Carcinoma in Situ

About this section
Sources:
17Gene Ontology
See all sources

Cellular components related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1focal adhesionGO:0059258.5SDC1, BRCA1, CDH1
2protein complexGO:0432348.1SDC1, TP53, BRCA2, BRCA1
3cytoplasmGO:0057377.3SDC1, TP53, BRCA2, BRCA1, ERBB2, CDH1

Biological processes related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:0716819.9CDH1, BRCA1
2response to X-rayGO:0101659.7BRCA2, TP53
3positive regulation of cell cycle arrestGO:0711589.7BRCA1, TP53
4cell agingGO:0075699.7TP53, BRCA2
5response to gamma radiationGO:0103329.6BRCA2, TP53
6intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:0427719.6BRCA2, TP53
7response to estrogenGO:0436279.5BRCA1, KRT19
8positive regulation of epithelial cell proliferationGO:0506799.5ERBB2, VEGFC
9double-strand break repair via homologous recombinationGO:0007249.4BRCA1, BRCA2
10DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:0069789.4BRCA1, BRCA2, TP53
11double-strand break repairGO:0063029.3TP53, BRCA2, BRCA1
12wound healingGO:0420609.1ERBB2, SDC1
13cell proliferationGO:0082839.1ERBB2, MET, TP53
14positive regulation of transcription, DNA-templatedGO:0458938.9TP53, BRCA2, BRCA1, CDH1

Molecular functions related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1protease bindingGO:0020209.5TP53, BRCA2
2glycoprotein bindingGO:0019488.9SDC1, CDH1
3protein phosphatase bindingGO:0199038.5TP53, MET, ERBB2, CDH1
4protein bindingGO:0055156.0VEGFC, SDC1, TP53, BRCA2, BRCA1, MET

Products for genes affiliated with Breast Carcinoma in Situ

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Breast Carcinoma in Situ

About this section
4CDC
14ExPASy
15FMA
23GTR
24HGMD
25HMDB
26ICD10
27ICD10 via Orphanet
28ICD9CM
30IUPHAR
31KEGG
36MeSH
37MESH via Orphanet
38MGI
41NCIt
42NDF-RT
45NINDS
46Novoseek
48OMIM
49OMIM via Orphanet
53PubMed
54QIAGEN
60SNOMED-CT via Orphanet
63UMLS
64UMLS via Orphanet